EATRIS enters framework agreement with Roche to access Europe-wide network of translational researchers
EATRIS, where University of Tartu is also a member, has signed a framework agreement with the Roche Partnering Extending Innovation Network (EIN) program. This agreement will facilitate EIN access to research projects within the EATRIS network of Principal Investigators from 70 academic research institutions in eight countries in Europe. The EATRIS-EIN program aims to accelerate translational research toward products that have direct therapeutic benefits for patients. The program will be formally launched on May 1, 2014.
Under this partnership, faculty-initiated research projects are selected for funding from proposals solicited EATRIS-wide on a continuous basis.
“The agreement with EIN marks the first formalized partnership with a major pharmaceutical company, in which EATRIS can accelerate access to important research that can provide significant patient benefits,” said Giovanni Migliaccio, Scientific Director of EATRIS. “Having access to the resources and know-how of an innovative company like Roche provides real added value to our research community.”
The EATRIS-EIN agreement aims at combining the know-how and expertise from Roche with the innovation potential of Europe’s leading academic scientists in order to accelerate the progression of therapeutic research projects towards the clinic, and further strengthen the cooperation between university research and pharmaceutical development. Existing partners within the EIN program include Harvard University, UC San Diego, UC San Francisco, as well as a partnership with various universities from Switzerland including Universities of Basel, Bern, and Zurich.
About EATRIS ERIC
EATRIS ERIC, the European Infrastructure for Translational Medicine is comprised of leading academic groups and institutions, in eight countries, which provide access to innovative translational research infrastructure and expertise. They leverage their state-of-the-art facilities and knowledge to reduce risks within translational research across Europe, while increasing productivity. Participating institutes are selected and continuously monitored on the basis of the available infrastructure, expertise and quality standards which comply with current European pharmaceutical regulations, laws and guidelines. As a European Research Infrastructure (ERIC), EATRIS headquarters provide ‘Coordination & Support’ activities in organizing one-stop access to over 70 research centres of excellence across Europe.